Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Armand, Philippe; Rodig, Scott; Melnichenko, Vladimir; Thieblemont, Catherine; Bouabdallah, Kamal; Tumyan, Gayane; ÖZCAN, MUHİT; Portino, Sergio; Fogliatto, Laura; Caballero, Maria; Walewski, Jan; Gulbas, Zafer; Ribrag, Vincent; Christian, Beth; Perini, Guilherme; Salles, Gilles; Svoboda, Jakub; Zain, Jasmine; Patel, Sanjay; Chen, Pei-Hsuan; Ligon, Azra; Ouyang, Jing; Neuberg, Donna; Redd, Robert; Chatterjee, Arkendu; Balakumaran, Arun; Orlowski, Robert; Shipp, Margaret; Zinzani, Pier

doi:10.1200/jco.19.01389

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Armand P., Rodig S., Melnichenko V., Thieblemont C., Bouabdallah K., Tumyan G., ...Daha Fazla

JOURNAL OF CLINICAL ONCOLOGY, cilt.37, sa.34, ss.3291-3301, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 37 Sayı: 34
Basım Tarihi: 2019
Doi Numarası: 10.1200/jco.19.01389
Dergi Adı: JOURNAL OF CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.3291-3301
Ankara Üniversitesi Adresli: Evet

Özet

PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet need. Because PMBCL is associated with genetic aberrations at 9p24 and overexpression of programmed cell death-1 (PD-1) ligands (PD-L1), it is hypothesized to be susceptible to PD-1 blockade.